Clinical Evaluation vs Investigation: Which Path MDR Forces You To Take

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The confusion between clinical evaluation and clinical investigation is not semantic. It represents a fundamental misreading of MDR requirements that surfaces late in the conformity assessment process, when correction is expensive and delays are inevitable.

I see this pattern repeatedly: manufacturers treat these two concepts as options on a menu, when in reality MDR Article 61 establishes a clear hierarchy and decision tree. Clinical evaluation is always required. Clinical investigation becomes mandatory when specific conditions are met. Understanding when those conditions apply is where most strategies fail.

The Regulatory Framework: What MDR Actually Requires

Article 61 of MDR 2017/745 establishes clinical evaluation as a mandatory element of the conformity assessment for all medical devices. There are no exceptions. Every device, regardless of class or intended purpose, must undergo clinical evaluation.

The clinical evaluation must follow a defined and methodologically sound procedure based on:

• Critical evaluation of relevant scientific literature
• Critical evaluation of available clinical data from equivalent devices
• Consideration of clinical investigation results
• Post-market clinical follow-up data

Clinical investigation, by contrast, is not always required. Article 61(4) and Article 61(5) define when a clinical investigation becomes mandatory, and MDCG 2020-13 clarifies the interpretation.

The decision is not yours to make freely. It is determined by the nature of your device, the novelty of your claims, and the sufficiency of available clinical evidence.

When Clinical Investigation Becomes Mandatory

Article 61(4) specifies that clinical investigations are required for implantable devices and Class III devices, unless specific conditions are met that justify reliance on existing clinical data.

The exceptions are narrow. You may avoid a clinical investigation if you can demonstrate equivalence to a device for which clinical evidence is already adequate. But equivalence must meet strict criteria defined in MDCG 2020-5: same clinical, biological, and technical characteristics, with no significant differences that could affect safety or performance.

This is where most strategies collapse. Manufacturers claim equivalence based on superficial similarities—same intended use, same material, similar design—without rigorously analyzing whether the available clinical data actually covers the specific claims they are making.

I have reviewed dozens of submissions where the manufacturer referenced a predicate device but failed to show that the clinical data for that device addressed the specific patient population, duration of use, or performance endpoints relevant to their own device. The Notified Body rightly rejected the equivalence claim. The manufacturer was forced back to clinical investigation, but now with timeline and budget damage already done.

The Reality of Equivalence Under MDR

Pre-MDR, equivalence was interpreted more loosely. Manufacturers could reference devices with broadly similar characteristics and argue that existing data was sufficient. Notified Bodies often accepted these arguments.

Under MDR, the equivalence threshold has risen significantly. MDCG 2020-5 establishes that equivalence cannot be claimed based solely on similar intended use or design. You must demonstrate that the clinical, biological, and technical characteristics are so closely aligned that any differences do not affect clinical safety or performance.

This means you need access to detailed technical and clinical information about the predicate device. If that device is manufactured by a competitor, you typically do not have this access. If the predicate device has only limited published clinical data, you cannot fill the gaps with assumptions.

The result: equivalence claims that looked reasonable under the Directives now fail under MDR. Manufacturers who planned to avoid clinical investigation find themselves required to conduct one anyway.

The strategic error is not technical. It is logical. They treated equivalence as a starting assumption rather than a conclusion that must be rigorously justified through documented analysis.

When Sufficient Clinical Evidence Exists Without Equivalence

Not all paths to avoiding clinical investigation depend on equivalence. Article 61(10) allows reliance on existing clinical evidence if it is sufficient to demonstrate conformity with the relevant general safety and performance requirements.

This applies most commonly to well-established device types where extensive clinical data exists in the scientific literature, and where your device does not introduce novel features or claims.

But sufficiency must be demonstrated, not assumed. Your clinical evaluation report must show that the available literature adequately addresses your specific intended purpose, patient population, duration of use, and performance claims. Any gaps must be acknowledged and justified.

I have seen manufacturers reference large volumes of literature without analyzing whether that literature actually covers the specific claims in their intended use. They submit a clinical evaluation report with 200 citations, but under scrutiny, only 15 of those studies are actually relevant to their device’s specific characteristics and use conditions.

Notified Bodies see through volume. They assess relevance, methodological quality, and applicability. If the clinical evidence does not adequately cover your claims, a clinical investigation becomes necessary to close the gap.

How to Determine Your Path Before Submission

The decision logic should be worked out early, not during Notified Body review. This requires a structured assessment conducted before you finalize your clinical development plan.

Start with device classification and risk profile. If you have a Class III or implantable device, clinical investigation is presumed necessary unless you can affirmatively demonstrate an exception applies.

Next, conduct a preliminary literature review and gap analysis. Identify the specific clinical claims you need to support. Map available clinical evidence to those claims. Document where evidence exists, where it is weak, and where it is absent.

If you intend to claim equivalence, perform a detailed comparison to the predicate device using the MDCG 2020-5 criteria. Do not rely on high-level similarities. Analyze technical specifications, materials, biocompatibility data, and clinical performance data. If you cannot access detailed information about the predicate device, your equivalence claim will likely fail.

Engage your Notified Body early with a preliminary clinical evaluation plan. Present your reasoning for why you believe existing evidence is sufficient or why equivalence applies. Let them challenge your assumptions before you commit resources.

This early engagement does not guarantee acceptance, but it surfaces problems when they are still manageable. Discovering that a clinical investigation is required after you have already submitted your technical file is a failure of planning, not a surprise from the regulation.

The Cost of Misreading the Requirements

The practical consequences of misunderstanding the clinical evaluation versus clinical investigation decision are severe. Clinical investigations require ethics approvals, study protocols, patient recruitment, data monitoring, statistical analysis, and often years of follow-up.

If you planned for a literature-based clinical evaluation and are forced into clinical investigation during Notified Body review, your timeline extends by 18 to 36 months. Your budget increases by hundreds of thousands to millions of euros, depending on device complexity and study design.

But the deeper cost is strategic. You lose competitive timing. You face extended market entry delays. And if you are in a capital-constrained environment, the funding implications can jeopardize the entire program.

I have seen companies forced to pivot from full market launch strategies to limited market release under investigational protocols, fundamentally altering their commercial plans because the clinical development strategy was based on faulty assumptions about what MDR would accept.

The regulatory framework is clear. The guidance documents are detailed. The problem is not ambiguity in the regulation. The problem is systematic underestimation of what constitutes sufficient evidence and valid equivalence under the current interpretation standards.

Building a Defensible Strategy

A defensible clinical development strategy starts with conservative assumptions. Assume that your evidence will be challenged. Assume that your equivalence claim will be tested rigorously. Assume that any gap in your clinical data will be identified.

Document your decision logic transparently in your clinical evaluation plan. Show that you considered whether a clinical investigation was necessary. Show the analysis that led you to conclude it was not. Reference specific MDCG guidance and MDR articles that support your reasoning.

If you proceed without a clinical investigation, ensure that your clinical evaluation report includes a detailed justification section explaining why the available evidence is sufficient and, if applicable, why equivalence is valid. Do not leave this reasoning implicit.

And build flexibility into your timeline and budget. If the Notified Body challenges your strategy, you need the capacity to respond. This might mean conducting additional literature searches, refining your equivalence analysis, or ultimately designing and executing a clinical investigation.

The regulatory pathway is not fixed at the start. It is confirmed through the conformity assessment process. Your job is to present the strongest possible justification for your chosen path and to be prepared to adapt if that justification is not accepted.

What This Means for Your Submission

Every clinical evaluation report submitted under MDR will be assessed against the question: Is the available clinical evidence sufficient to demonstrate conformity with the applicable general safety and performance requirements?

If the answer is yes, and the device is not Class III or implantable, or if valid equivalence or sufficient literature exists, then clinical investigation may not be required. But that “yes” must be substantiated with rigorous analysis, not asserted.

If the answer is no, or if there is uncertainty, then clinical investigation becomes the path forward. Resistance to this conclusion does not change the regulatory requirement. It only delays the inevitable and increases the cost of compliance.

The decision between clinical evaluation alone and clinical evaluation supported by investigation is not a strategic choice. It is a logical outcome of the evidence available, the device characteristics, and the claims being made. Misunderstanding this is not a regulatory interpretation issue. It is a failure to read the framework correctly.

Your conformity assessment strategy should reflect this reality from day one.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.